Impacto do uso de probióticos e simbióticos em pessoas com doença renal: uma revisão de literatura
DOI:
https://doi.org/10.34119/bjhrv6n3-253Keywords:
doença renal, probióticos, microbiotaAbstract
Introdução: Alterações na composição da microbiota intestinal, associadas ao crescimento de espécies bacterianas envolvidas na geração de toxinas urêmica tem sido observadas em pessoas com doença renal. Assim, a suplementação de probióticos e simbióticos tem sido sugerida como terapia adjuvante para o equilíbrio da microbiota contribuindo para a integridade da barreira intestinal e controle metabólico desses pacientes. Objetivo: Verificar os efeitos da utilização de prebióticos, probióticos ou simbióticos no tratamento de pessoas com doença renal. Metodologia: Revisão de literatura realizada durante o período de janeiro de 2023 incluindo estudos dos últimos cinco anos, caracterizada pela pergunta norteadora: “impacto do uso de probióticos e simbióticos na microbiota de pessoas com doença renal”. Foram utilizadas as bases de dados Pubmed, SciELO e LILACS e descritores em português e inglês das palavras: “doença renal”, “probióticos” e “microbiota” combinados através do operador “AND”. Resultados e discussão: Foram incluídos sete artigos publicados entre 2018 e 2022. De todos os estudos, seis encontraram benefícios na administração de probióticos ou simbióticos e um não encontrou benefícios. Os estudos que consideraram benefícios, demonstraram redução de marcadores inflamatórios, redução da disbiose intestinal e melhora nos parâmetros renais de um modo geral. Conclusão: A suplementação de simbióticos parece viável em determinado tempo e sob supervisão profissional para adultos com doença renal, auxiliando em seu tratamento, de modo a promover uma ação sinérgica e eficaz.
References
AGUIAR LK, et al. Fatores associados à doença renal crônica: inquérito epidemiológico da Pesquisa Nacional de Saúde. Revista Brasileira de Epidemiologia, 2020; 2(2): 1-23.
Al Khodor S., Shatat I.F. Gut microbiome and kidney disease: a bidirectional relationship. Pediatr Nеphrol. 2017;32(6):921–931. doi: 10.1007/s00467-016-3392-7.
Barros AF, Borges NA, Ferreira DC, et al. Is there interaction between gut microbial profile and cardiovascular risk in chronic kidney disease pa tients? Future Microbiol. 2015;10:517-526.
Bastos MG, Kirsztajn GM. Chronic kidney disease: importance of early diagnosis, immediate referral and structured interdisciplinary approach to improve outcomes in patients not yet on dialysis. J Bras Nefrol 2011; 33(1): 93-108.
Belova IV, Khrulev AE, Tochilina AG, Khruleva NS, Lobanova NA, Zhirnov VA, Molodtsova SB, Lobanov VN, Solovieva IV. Colon Microbiocenosis and Its Correction in Patients Receiving Programmed Hemodialysis. Sovrem Tekhnologii Med. 2021;12(5):62-68. doi: 10.17691/stm2020.12.5.07. Epub 2020 Oct 28. PMID: 34796006; PMCID: PMC8596268.
BORGES NA, CARMO FL, STOCKLER-PINTO MB, ROSADO A, FOUQUE MD, MAFRA D, , Probiotic Supplementation in Chronic Kidney Disease: A Double-blind, Randomized, Placebo-controlled Trial. Journal of Renal Nutrition, Vol 28, No 1 (January), 2018: pp 28-36. https://doi.org/10.1053/j.jrn.2017.06.010
Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-1264.
Campos CA, Rodriguez O, Calo-Mata P et al (2006) Preliminary characterization of bacteriocins from Lactococcus lactis, Entero coccus faecium and Enterococcus mundtii strains isolated from turbot (Psetta maxima). Food Res Int 39:356–364.
Chen F, Jiang J, Tian DD, et al. Visando a obesidade para a prevenção de doenças cardiovasculares crônicas por meio de interações entre microbiota intestinal e ervas: uma oportunidade para as ervas tradicionais. Curr Pharm Des. 2017; 23 :1142–1152. doi: 10.2174/1381612822666161014115724.
Cosola C, Rocchetti MT, di Bari I, Acquaviva PM, Maranzano V, Corciulo S, Di Ciaula A, Di Palo DM, La Forgia FM, Fontana S, De Angelis M, Portincasa P, Gesualdo L. Sulfato de indoxil sérico, permeabilidade do intestino delgado e melhora os sintomas gastrointestinais em um estudo piloto randomizado em pacientes com DRC em estágio IIIb-IV. Toxinas . 2021; 13(5):334. https://doi.org/10.3390/toxins13050334.
D’Onofrio G, Simeoni M, Rizza P, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail. 2017;39:45–53. doi: 10.1080/0886022X.2016.1244077.
De Mauri A, Carrera D, Bagnati M, Rolla R, Vidali M, Chiarinotti D, Pane M, Amoruso A, Del Piano M. Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial. Nutrients 2022, 14, 1637. https://doi.org/10.3390/nu14081637. https://doi.org/10.3390/nu14081637.
Dizman N, Hsu J, BergerotPG, e outros. Ensaio randomizado avaliando o impacto desuplementação probiótica no microbioma intestinal eresultado clínico da terapia alvo em metastáticocarcinoma de células renais.câncer med. 2021;10:79–86.https://doi.org/10.1002/cam4.3569
Evenepoel P, Meijers BK. Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. Kidney Int. 2012;81:227–229. doi: 10.1038/ki.2011.394.
Fagundes RAB, Soder TF, Grokoski KC, Benetti F, Mendes RH. Probiotics in the treatment of chronic kidney disease: a systematic review. J Bras Nefrol. 2018;40(3):278-86. doi: http://dx.doi.org/10.1590/2175-8239-jbn-3931. PubMed PMID: 29958304.
Feng Z, Wang T, Dong S, Jiang H, Zhang J, Raza HK, et al. Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature. J Int Med Res. 2021;49(10):3000605211053276. doi: http://dx.doi.org/10.1177/03000605211053276. PubMed PMID: 34704483.
Foulquie Moreno MR, Sarantinopoulos P, Tsakalidou E, De Vuyst L (2006) The role and application of Enterococci in food and health. Int J Food Microbiol 106:1–24. https://doi.org/10.1016/j. ijfoodmicro.2005.06.026.
Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7:503–514. https://doi.org/10.1038/nrgas tro.2010.117
Gibson, GR; Roberfroid, MB Modulação dietética da microbiota colônica humana: Apresentando o conceito de prebióticos. J. Nutr. 1995 , 125 , 1401–1412.
Kang JY (1993) The gastrointestinal tract in uremia. Dig Dis Sci 38:257–268 (PMID:8425438)
Kim M-S, Hwang S-S, Park E-J, Bae J-W. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep. 2013;5:765–775. doi: 10.1111/1758-2229.12090.
Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015;88(5):958-66. doi: http://dx.doi.org/10.1038/ki.2015.255. PubMed PMID: 26376131.
Liu J, Zhong JY, Yang HC, Wang DQ, Zhang Y, Yang YM, et al. Biotic supplements in patients with chronic kidney disease: meta-analysis of randomized controlled trials. J Ren Nutr. 2022;32(1):10-21. doi: http://dx.doi.org/10.1053/j.jrn.2021.08.005. PubMed PMID: 34666930.
Mafra D, Barros AF, Fouque D. Dietary protein metabolism by gut microbiota and its consequences for chronic kidney disease patients. Future Microbiol. 2013;8:1317–1323. doi: 10.2217/fmb.13.103.
Mafra, D.; Lobo, JC; Barros, AF; Koppe, L.; Vaziri, ND; Fouque, D. Papel da microbiota intestinal alterada na inflamação sistêmica e doença cardiovascular na doença renal crônica. Futuro Microbiol. 2014 , 9 , 399–410.
McFarlane C, Krishnasamy R, Stanton T, Savill E, Snelson M, Mihala G, Kelly JT, Morrison M, Johnson DW, Campbell KL. Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. Nutrients 2021, 13, 4481. https://doi.org/10.3390/nu13124481.
Miranda Alatriste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas Mde L. Effect of probiotics on human blood urea levels in pa tients with chronic renal failure. Nutr Hosp. 2014;29:582-590.
Moraes C, Borges NA, Mafra D. Resistant starch for modulation of gut microbiota: promising adjuvant therapy for chronic kidney disease patients? Eur J Nutr. 2016;55:1813-1821.
Natarajan R, Pechenyak B, Vyas U, et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int. 2014;2014:568571.
NERBASS FB, LIMA HN, THOMÉ FS, VIEIRA NETO OM, LUGON JR, SESSO R. Pesquisa Brasileira de Diálise 2020. Braz. J. Nephrol., v. 44, n. 3, pág. 349-357, fev. 2022. <https://www.scielo.br/j/jbn/a/3Jts9Jdpcy5vc5MFjdMwV3g/?format=pdf&lang=en>
Nistor I., Palmer S.C., Craig J.C., Saglimbene V., Vecchio M., Covic A., Strippoli G.F.M. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev. 2015;5:CD006258. doi: 10.1002/14651858.CD006258.pub2.
Pham P-CT, Toscano E, Pham P-MT, et al. Pain management in patients with chronic kidney disease. NDT Plus. 2009;2:111–118.
Ramezani A, Massy ZA, Meijers B et al (2016) Role of the gut microbiome in uremia: a potential therapeutic target. Am JKidney Dis Off J Natl Kidney Found 67:483–498. https://doi. org/10.1053/j.ajkd.2015.09.027.
Ramezani A, Raj DS. The gut microbiome, kidney disease, and tar geted interventions. J Am Soc Nephrol. 2014;25:657-670.
Rampino T, Gregorini M, Camussi G et al (2005) Hepatocyte growth factor and its receptor Met are induced in crescen tic glomerulonephritis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 20:1066–1074. https://doi. org/10.1093/ndt/gfh740.
Ranganathan N, Ranganathan P, Friedman EA, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther. 2010;27:634-647.
Sabatino A, Regolisti G, Brusasco I et al (2015) Alterations of intestinal barrier and microbiota in chronic kidney disease. Neph rol Dial Transplant Off Publ Eur Dial Transpl Assoc. Eur Ren Assoc 30:924–933. https://doi.org/10.1093/ndt/gfu287.
Sanders ME (2008) Probiotics: definition, sources, selection, and uses. Clin Infect Dis Off Publ Infect Dis Soc Am 46(Suppl 2):S58–S61. https://doi.org/10.1086/523341
Sesso RC, Lopes AA, Thomé FS, Lugon JR, Martins CT. Brazilian chronic dialysis census 2014. J Bras Nefrol 2016; 38(1):54-61.
Simeoni M, Armeni A, Summaria C, et al. Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney. Ren Fail. 2017;39:660–670. doi: 10.1080/0886022X.2017.1361840.
Simeoni M, Cerantonio A, Pastore I, et al. The correct renal function evaluation in patients with thyroid dysfunction. J Endocrinol Invest. 2016;39:495–507. doi: 10.1007/s40618-015-0402-8.
Simeoni M, Citraro ML, Cerantonio A, Deodato F, Provenzano M, Cianfrone P, Capria M, Corrado S, Libri E, Comi A, Pujia A, Abenavoli L, Andreucci M, Cocchi M, Montalcini T, Fuiano G. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD). Eur J Nutr. 2019 Aug;58(5):2145-2156. doi: 10.1007/s00394-018-1785-z. Epub 2018 Aug 3. Erratum in: Eur J Nutr. 2018 Oct 9;: PMID: 30076458; PMCID: PMC6647244.
Simeoni M, Damiano S, Capolongo G, et al. Rare renal diseases can be used as tools to investigate common kidney disorders. Kidney Dis Basel Switz. 2017;3:43–49. doi: 10.1159/000475841.
Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46:S104- S111.
Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seam less capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003;41:S142-S145.
Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastro resistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr. 2005;15:77-80.
Tursi A, Giorgetti GM, Brandimarte G, Elisei W (2005) High prevalence of celiac disease among patients affected by Crohn’s disease. Inflamm Bowel Dis 11:662–666.
Urben LM, Wiedmar J, Boettcher E, Cavallazzi R, Martindale RG, McClave SA. Bugs or drugs: are probiotics safe for use in the critically ill? Curr Gastroenterol Rep. 2014;16:388.
Vanholder, R.; De Smet, R.; Glorieux, G.; Argiles, A.; Baurmeister, U.; Brunet, P.; Clark, W.; Cohen, G.; De Deyn, PP; Deppisch, R.; e outros Trabalho Europeu sobre Toxina Urêmica (EUTox). Revisão sobre toxinas urêmicas: classificação, concentração e variabilidade interindividual. Rim Int. 2003, 63 , 1934-1943.
Vaziri N.D, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: The nature, mechanisms, consequences and potential treatment. Nephrol. Dial. Transplant. 2015, 31, 737–746.
Vaziri N.D. Gut microbial translocation in the pathogenesis of systemic inflammation in patients with end-stage renal disease. Dig Dis Sci. 2014;59(9):2020–2022. doi: 10.1007/s10620-014-3287-z.
Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83:308–315. doi: 10.1038/ki.2012.345.
Wong J., Piceno YM, DeSantis TZ, Pahl M., Andersen GL, Vaziri ND. Expansão de urease e contendo uricase, formação de indol e p-cresol e contração de bactérias intestinais produtoras de ácidos graxos de cadeia curta em ESRD. Am J Nephrol. 2014; 39 : 230-237.
